1.
|
Phase: Phase IV
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 10720, H3E-MC-JMIC, NCT00380718
|
|
2.
|
Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI, Pharmaceutical / Industry
Protocol IDs: MSKCC-99085, CWRU-LILY-1599, LILLY-H3E-MC-JMCH(a), NCI-G00-1767, NCT00005636
|
|
3.
|
Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI, Pharmaceutical / Industry
Protocol IDs: CWRU-010224M, NCI-G02-2125, LILLY-H3E-MC-JMES, LILLY-LILY-1201, NCT00049426
|
|
4.
|
Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 8433, H3E-MC-JMGX, NCT00078260
|
|
5.
|
Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 2938, H3E-MC-JMDB, NCT00087711
|
|
6.
|
Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 5122, H3E-MC-JMEN, NCT00102804
|
|
7.
|
Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 10717, H3E-MC-JMID, NCT00391274
|
|
8.
|
Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: D4200C00036, EUDRACT No. 2006-003695-35, NCT00418886
|
|
9.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCCTG-N9943, N9943, NCT00059865
|
|
10.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 7221, H3E-US-JMGC, NCT00071136
|
|
11.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 2927, H3E-MC-JMDO, NCT00034502
|
|
12.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 4028, H3E-MC-JMDU, NCT00097383
|
|
13.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 9439, H3E-US-S066, NCT00101842
|
|
14.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: HOG LUN04-79, NCT00216203
|
|
15.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Temporarily closed
Age: 18 and over
Sponsor: Other
Protocol IDs: NVCI05-14, NCT00281125
|
|
16.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: M05-780, NCT00297089
|
|
17.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 4029, H3E-MC-JMDV, NCT00190671
|
|
18.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: 18 to 70
Sponsor: Pharmaceutical / Industry
Protocol IDs: 7461, H3E-AA-S038, NCT00320515
|
|
19.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: UCDCC-159, UCDCC-200412741-2, NCT00387322
|
|
20.
|
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: UCDCC-158, UCDCC-200412739-2, NCT00389805
|
|
21.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 8679, H3E-ES-S085, NCT00374868
|
|
22.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: MKC-102, NCT00408226
|
|
23.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Other
Protocol IDs: 2006-005970-26, KKS / INNERE_A / NSCLC2006, NCT00473486
|
|
24.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 9516, H3E-MC-JMHH, NCT00489359
|
|
25.
|
Phase: Phase II
Type: Treatment
Status: Closed
Age: 16 and over
Sponsor:
Protocol IDs: CAN-NCIC-IND89, NCI-V95-0755, IND89
|
